Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model. Slof J, Gras A Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 8. PMID: 22681512. Abstract CommentRecommendBookmarkWatch